Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Date : 10/28/2019 @ 9:15PM
Source : GlobeNewswire Inc.
Stock : Assembly Biosciences Inc (ASMB)
Quote : 16.63  0.2 (1.22%) @ 1:00AM
After Hours
Last Trade
Last $ 16.63 ◊ 0.00 (0.00%)

Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart

2 Months : From Oct 2019 to Dec 2019

Click Here for more Assembly Biosciences Charts.

Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of inducement awards to its Chief Financial Officer, Thomas J. Russo, CFA on October 28, 2019.

The Company granted Mr. Russo non-qualified stock options to purchase 185,000 shares of the company’s common stock with an exercise price of $15.69 per share, the closing price of Assembly’s common stock as reported by Nasdaq on October 28, 2019. The option grant was made as a material inducement to Mr. Russo to accept the Company’s offer of employment as its Chief Financial Officer. The stock options have a ten-year term and vest over four years, with one-fourth vesting on the first anniversary of the date of grant and the remaining three-fourths vesting in substantially equal monthly installments over the next 36 months. The options are subject to Mr. Russo’s continued service with Assembly through the applicable vesting dates and to acceleration upon the occurrence of certain events as set forth in the award agreement evidencing the options. 

The option grant was granted outside of Assembly’s stockholder-approved equity incentive plans pursuant to Assembly’s 2017 Inducement Award Plan. The stock options were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to Mr. Russo entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Assembly Biosciences Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.

Contacts Assembly Biosciences, Inc. Investors: Lauren Glaser (415) 521-3828 lglaser@assemblybio.com

Latest ASMB Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.